Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies

Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the
Treatment of Two Difficult-to-Treat Epilepsies
August 21, 2009

DEERFIELD, Ill.--(BUSINESS WIRE)--Aug 21, 2009 - Lundbeck Inc.
("Lundbeck"), a wholly owned subsidiary of H. Lundbeck A/S in Denmark
(Copenhagen: LUN), announced today that the U.S. Food and Drug
Administration (FDA) has granted two New Drug Application (NDA)
approvals for Sabril (vigabatrin) Tablets and Oral Solution. Lundbeck
plans to launch Sabril in the United States in the third quarter.